You are here: Industry Insights > S-Trimer

News List

First Participants Dosed in Adjuvanted S-Trimer COVID-19 Vaccine Candidate Trial americanpharmaceuticalreview
April 01, 2021
Clover Biopharmaceuticals and Dynavax Technologies announced the first participants have been dosed in Clover's SPECTRA trial (Study Evaluating Protective-Efficacy and Safety of Clover's Trimeric Recombinant Protein-based and Adjuvanted COVID-19 ...
Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet prnasia
February 01, 2021
Clover Biopharmaceuticals today announced that the data from its Phase 1 clinical trial evaluating the safety and immunogenicity of its protein-based adjuvanted S-Trimer COVID-19 vaccine candidates was published in the peer-reviewed journal, The Lancet.
CEPI to fund Clover’s Covid-19 vaccine development pharmaceutical-technology
November 06, 2020
The Coalition for Epidemic Preparedness Innovations (CEPI) has extended its partnership to fund the development of Sichuan Clover Biopharmaceuticals’ protein-based S-Trimer Covid-19 vaccine candidate.